Coherus Oncology, Inc. (FRA:8C5)

Germany flag Germany · Delayed Price · Currency is EUR
1.459
+0.259 (21.58%)
At close: Jan 9, 2026
-8.70%
Market Cap175.61M
Revenue (ttm)236.71M
Net Income (ttm)132.08M
Shares Outn/a
EPS (ttm)1.14
PE Ratio1.33
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume900
Average Volume221
Open1.294
Previous Close1.200
Day's Range1.294 - 1.459
52-Week Range0.608 - 1.571
Betan/a
RSI68.92
Earnings DateMar 6, 2026

About Coherus Oncology

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 mono... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Employees 228
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 8C5
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.